It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Identify passive funds with low turnover to improve tax efficiency and stability. Compare options and select high-quality, low-turnover strategies.
27,282 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Markets are sizing Coca-Cola for a two-year path as AI-driven capital shifts reshape sectors. A fresh price predictio...
Music, movies, and TV can influence how you feel—and how you spend. This guide reveals the mood-money link and offers...
Pixelworks' 2025 earnings cycle highlights a niche semiconductor with rising AI-driven display capabilities. This art...
Oracle is at a crossroads: AI-enabled cloud growth and savvy capital management could unlock significant upside. Here...
AT&T stunned investors with a record quarter, accelerating buybacks and signaling a robust cash flow backdrop. Here’s...
Franklin Templeton filed for two DRIP-focused ETFs that would redirect dividend payouts from U.S. stocks into Bitcoin...
Banks are reviving sign-up bonuses on savings accounts as competition for deposits intensifies. This article breaks d...
A Minnesota food vendor case highlights risks in federal child nutrition programs. Learn how the scheme worked, who’s...
Bitcoin trades around $55K as ETFs diverge in approach. This timely analysis explains what bitcoin $55k means for IBI...
A 73-year-old worker with an $800,000 401(K) cannot roll it into a new IRA after leaving a former employer, revealing...
Veteran investor Mark Kvamme is rolling out a Temasek style OHIO Fund, a $500 million vehicle aimed at accelerating g...